Pneumococcal Vaccine Market Size, Share, By Vaccine Type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, Pneumovax 23, PNEUMOSIL, and Others), Sector (Public and Private), Distribution Channel

Pneumococcal Vaccine Market Size, Share, By Vaccine Type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, Pneumovax 23, PNEUMOSIL, and Others), Sector (Public and Private), Distribution Channel (Distribution partner companies, Non-governmental organization, Government Authorities, and Others), and Region - Trends, Analysis and Forecast till 2035

The pneumococcal vaccine market is growing due to increased focus on immunization programs, awareness of vaccine-preventable diseases, and government initiatives. The market expansion is driven by the development of newer, advanced vaccines, combating serotype replacement concerns, and technological advancements in pneumococcal vaccines, which help protect against invasive diseases, reduce hospitalizations, and protect chronic respiratory diseases.

The Pneumococcal Vaccine Market Report offers an in-depth exploration of emerging market trends, driving factors, challenges, and key segments that shape the industry. It includes a thorough examination of regulatory frameworks, company profiles, and the latest industry developments. The report delves into product development, positioning strategies, and the impact of new technologies on the market landscape. By identifying challenges and opportunities, the report provides a detailed roadmap for market growth.

Report Highlights:

• Pneumococcal vaccine market size is accounted at USD 8.8 Billion in 2025.
• Target market size is estimated to grow at a valuation of USD 15.5 Billion by 2035 and at a registered CAGR of 6.3%.
• Based on vaccine type, the pneumococcal vaccines segment is expected to dominate the pneumococcal vaccine market share.
• By product type, Prevnar 13 segment is projected to rule over the pneumococcal vaccine market.
• On the basis of sector, the public sector is the governing segment of the target market.
• According to distribution channel, the distribution partner companies is influencing the pneumococcal vaccine market.
• Geographically, North America is the region which is anticipated to lead the pneumococcal vaccine market share.
• Europe is the region, which has the pneumococcal vaccine market growing with the fastest growth rate, during the forecast period.

Key Highlights:

In June 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease caused by Streptococcus pneumonia. CAPVAXIVE was specifically designed to help protect adults against the serotypes that caused the majority of invasive pneumococcal disease (IPD) cases. The approval followed the FDA’s Priority Review of Merck’s application.

Report Analysis:

Diseases Caused by Pneumococcus:

The pneumococcal vaccine protects children from potentially serious, and even life-threatening infections caused by pneumococcus bacteria, which include (a) pneumococcal meningitis (an infection of the tissue covering the brain and spinal cord) and (b) pneumonia (lung infection). While pneumonia is a serious condition, meningitis can cause lifelong disability, or death. The Pneumococcus is also a common cause of ear infections. Children younger than 5 years and the elderly more than 65 years, are among those most at risk for the disease. Children with weak immune systems are at highest risk of infection and complications. The disease spreads when an infected person coughs or sneezes.

Segmentation:

By Vaccine Type:

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

By Product Type:

• Prevnar 13
• Synoflorix
• Pneumovax 23
• PNEUMOSIL
• Others

By Sector:

• Public
• Private

By Distribution Channel:

• Distribution Partner Companies
• Non-Governmental Organization
• Government Authorities
• Others

By Region:

• North America

o U.S.

Canada

• Europe

o Germany

U.K.

France

Russia

Italy

Spain

Netherlands

Rest of Europe

• Asia Pacific

o China

India

Japan

Australia

Indonesia

Malaysia

South Korea

Rest of Asia Pacific

• Latin America

o Brazil

Mexico

Argentina

Rest of Latin America

• Middle East & Africa

o GCC

Israel

South Africa

Rest of Middle East & Africa

The report also includes a competitive analysis with a detailed SWOT review, examining the strengths, weaknesses, opportunities, and threats of each leading company, as well as their market share and product offerings.

List of Key Players in the Market:

Pfizer Inc.

Merck & Co., Inc.

GSK plc

Sanofi

Shenzhen Kangtai Biological Products Co., Ltd.

Walvax Biotechnology Co., Ltd.

Serum Institute of India Pvt. Ltd

AIM Vaccine Co., Ltd.

Precision Vax LLC

Beijing Minhai Biological Technology Co., Ltd.

Astellas Pharma Inc.

Panacea Biotec

Inventprise

Abbott

What Our Report Delivers:

• Regional & Country-Level Market Insights: Detailed market share analysis across key regions and countries to help you understand competitive positioning.
• Guidance for New Market Players: Actionable strategic recommendations for businesses entering the market, ensuring a strong foothold from the start.
• Comprehensive Market Forecasts: Reliable data projections for 2024, 2025, 2026, 2028, and 2032 to support long-term planning and investment decisions.
• In-Depth Market Dynamics: Analysis of drivers, restraints, opportunities, and emerging threats, along with challenges and high-potential investment areas.
• Data-Driven Business Strategies: Expert recommendations tailored to key market segments, backed by precise market evaluations.
• Competitive Intelligence: Mapping of prevailing industry trends and competitor strategies to identify growth opportunities.
• Detailed Company Profiles: In-depth analysis of major players, including their business strategies, financial performance, and recent developments.
• Supply Chain Innovations: Insights into the latest technological advancements and trends shaping supply chain efficiency.

FAQs:

Key Questions Answered in the Report.

What was the Pneumococcal Vaccine Market size in 2025?

What is projected growth rate of the Pneumococcal Vaccine Market during 2025-2035?

What are the key factors driving the Pneumococcal Vaccine Market growth?

What are leading players in the Pneumococcal Vaccine Market ?

What are the key regions analyzed in the Pneumococcal Vaccine Market ?

Which region is dominating in the Pneumococcal Vaccine Market ?